ReviewCureus2022
Impact of Catheter Ablation on Long-Term Outcomes in Patients With Atrial Fibrillation: A Meta-Analysis.
Review in Cureus, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed, 10 citations in OpenAlex.
- Efficacy of ablation therapy on clinical outcomes in patients with atrial fibrillation: a systematic review and meta-analysis.Annals of medicine and surgery (2012) · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 7 institutions in 6 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The role of catheter ablation in patients with atrial fibrillation (AF) in enhancing long-term outcomes remains unknown. This meta-analysis aimed to assess the impact of catheter ablation on stroke, all-cause mortality, hospitalization due to heart failure, and major bleeding events in patients with atrial fibrillation. This meta-analysis was conducted in compliance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines. The data search was carried out by two authors independently using online databases including PubMed, EMBASE, and Cochrane library. The primary outcome was a stroke. The secondary outcomes were all-cause mortality, hospitalization for heart failure, and major bleeding events. Total, 10 articles were included in the current meta-analysis encompassing 275392 patients (33291 in the ablation group and 244974 in the non-ablation group). Among all included studies, one study was a randomized control trial, while the remaining other were retrospective cohorts. The current meta-analysis showed that catheter-based AF ablation reduced the risk of stroke (hazard ratio {HR}: 0.61, 95% CI: 0.49-0.77), all-cause mortality (HR: 0.60, 95% CI: 0.51-0.71), and hospitalization for heart failure (HR: 0.57, 95% CI: 0.43-0.76). No significant differences were reported in terms of major bleeding events between patients who received catheter-based AF ablation and patients who did not receive catheter-based AF ablation (HR: 0.96, 95% CI: 0.80-1.14). In the current meta-analysis, catheter-based AF ablation was associated with decreased risk of all-cause mortality, stroke, and hospitalization due to heart failure. However, no significant difference was reported in terms of major bleeding events.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.